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V ascular calcification is one of the major complications of cardiovascular disease and an independent risk factor for myocardial infarction and cardiac death, 1 among other outcomes. Arterial calcification is also associated with osteoporosis, especially in postmenopausal women. 2 Recent evidence strongly suggests the biological linkages on both disease mechanisms based on the presence of bone-related proteins 3 and bone-related cells at the site of calcification. 4 Accordingly, a triad of key proteins in bone metabolism has emerged as new players in cardiovascular diseases: RANK (the receptor activator of nuclear factor B), the RANK ligand (RANKL), and osteoprotegerin (OPG).
In bone, RANKL and OPG are expressed in osteoblasts, and the receptor RANK is expressed in osteoclast cells. The major role of RANKL in bone is the stimulation of osteoclast activity 5 and inhibition of osteoclast apoptosis. 6 RANKL binds not only to RANK but also to OPG, 7, 8 which is secreted as a soluble protein that lacks transmembrane and cytoplasmic domains. Because of this peculiarity of a decoy receptor, the major biological action described for OPG has been through the binding to RANKL and consequent inhibition of RANK stimulation, then decreasing the osteoclast differentiation and activity in bone. 7, 8 OPG-deficient mice develop severe osteoporosis resulting from marked increase in osteoclast activation, and interestingly two-thirds of the animals have profound vascular medial calcification. 9 Similar to OPG-deficient mouse phenotype, postmenopausal women also have high incidence of osteoporosis and vascular calcification, 10 which suggests that RANK-RANKL system may work not only in osteoporosis but also in arterial calcification.
Estrogen regulates bone metabolism by inducing osteoclast apoptosis 11 and osteoblast expression of OPG, 12 and estrogen also inhibits vascular lesion progression, 13 promotes favorable alterations in lipoprotein metabolism, 14 and controls adhesion molecules, contributing to antiinflammatory responses in vasculature. 15 In the controlled Women's Health Initiative Study, postmenopausal women aged 50 to 59 years treated with long-term estrogen therapy had lower levels of coronary artery calcification than those who received placebo. 16 However, the relationship between estrogen deficiency and arterial calcification has not been fully clarified, with only a recent study confirming the positive correlation of the incidence of both pathologies in an animal model. 17 In the present study, we focus in the crosstalk of RANKL system and estrogen as the common pathway regulating aortic calcification and osteoporosis.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
In Vitro Experiment
Materials PMA (phorbol 12-myristate, 13-acetate), 17␤-estradiol (E4389), and ICI-182,780 (I4409) were obtained from Sigma (St Louis, Mo). Recombinant human soluble RANKL and bone morphogenetic protein (BMP)-2 were purchased from Peprotech EC (London, UK). Anti-human OPG-neutralizing antibody was acquired from Cell Sciences (Canton, Mass). Anti-human RANK, RANKL, and RUNX2/CBFA1 (runt-related transcription factor 2/core binding factor ␣1) antibodies and recombinant human Noggin Fc chimera were purchased from R&D Systems (Minneapolis, Minn). Antihuman BMP-2, matrix Gla protein (MGP) (N-20) and anti-␤-actin antibody were acquired from Santa Cruz Biotechnology (Santa Cruz, Calif). Anti-phospho-smad-1/5/8 antibody was obtained from Cell Signaling Technology (Beverly, Mass). We purchased the ER␣ agonist 4,4Ј,4Љ-(4-Propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol (PPT) and ER␤ agonist 2,3-bis(4-Hydroxyphenyl)-propionitrile (DPN) from Tocris Bioscience (Ellisville, Mo).
Cell Culture
Human aortic vascular smooth muscle cells (HASMCs), HAECs, and normal human osteoblasts (OBs) were obtained from Lonza Walkersville Inc (Walkersville, Md). THP1 cells were purchased from American Type Culture Collection (Rockville, Md) and were activated into macrophage by PMA (phorbol 12-myristate, 13-acetate) as described previously. 18 For detailed cell culture procedures, refer to the Online Methods section.
Relative Quantification of mRNA by Real-Time PCR
The detailed procedure is described in the Online Methods section.
Western Blot Analysis
Western blot analysis was performed as described previously. 19 Briefly, total protein (10 g) was isolated using lysis buffer, size-fractioned by SDS-PAGE, and transferred to Immobilon-P membrane purchased from Millipore (Bedford, Mass). The blotted protein was incubated with antibodies after indicated treatment. The detailed procedure is described in the Online Methods section.
Calcification Induction
Calcified nodule formation was induced in HASMCs by the Osteogenic Induction Medium (Lonza). The detailed preparation of HASMCs is described in the Online Methods section.
Detection of Calcified Nodule
Cells were washed with HEPES buffer, and fixed with 4% PFA during 45 minutes at 4°C. The cells were washed again with water, stained with Alizarin red, 20 and the nodules were visualized in the light microscope.
Small Interfering RNA Transfection
MGP expression was silenced with the transfection of Silencer small interfering (si)RNA (siRNA ID: 122163) (Applied Biosystems, Foster City, Calif) with Lipofectamine 2000 (Invitrogen, Carlsbad, Calif) as the transfection agent. siRNA transfection was performed for 24 hours preceding subsequent stimulations in HASMCs.
Animal Experiments

Animal Preparation
Female apolipoprotein (Apo)E-deficient mice on a C57/Bl6 background were obtained from The Jackson Laboratory (Bar Harbor, Me).
Experimental Design
Female ApoE-deficient mice (nϭ45) were ovariectomized or shamoperated and treated with 20 g/kg per day 17␤-estradiol (E2) or saline and fed with normal or Western high-fat (HF) diet for 3 months. The detailed animal experiment design is described in the Online Methods section.
Histological Analysis of Atherosclerotic Lesions
Lipid deposition was detected by Oil red staining. Calcium deposition was visualized by Alizarin red staining, and the area was traced and quantified using BZ-II Analyzer (Keyence, Tokyo, Japan). The detailed procedure is described in the Online Methods section.
In Situ Hybridization
In situ hybridization was performed as described previously. 21 Sections were made at 8-m thickness, and the cDNAs used for generation of Dig-labeled mouse riboprobes were osteopontin 
Histological Analysis of Proximal Tibia
Osteoclasts were detected in proximal tibia by tartrate resistance acid phosphatase (TRAP) staining as described previously. 22 
Microcomputed Tomography
The tibias were collected and fixed with 4% PFA. Bone density measurements were performed by dual-energy x-ray absorptiometry (GE-Lunar DPX-IQ; Madison, Wis) and microcomputed tomography (x-ray computed tomography system, SMX-100CT-SV; Shimazu, Osaka, Japan) and software TRI/3D-BON (RATOC System Engineering Co Ltd, Tokyo, Japan) as described previously. 23 
Statistical Analysis
All values are expressed as meansϮSEM. ANOVA with subsequent Fisher's protected least significant difference test was used to determine the significance of differences in multiple comparisons.
Results
RANK, RANKL, and OPG System in Vasculature
The expression levels of RANK, RANKL, and OPG in human primary vascular cells were assessed by real-time PCR and Western blot analysis. RANK was observed in HAECs, HASMCs, but not, as expected, in OBs; RANKL expression was mainly observed in OBs, also detected in HASMCs, and at lower level in HAECs. OPG mRNA was mainly expressed in HASMCs ( Figure 1A) , and the protein level was confirmed in HAECs and HASMCs ( Figure 1B ). Overall, these data suggest that because of receptor RANK expression, vascular cells may respond to stimulation with RANKL, and can regulate the RANK stimulation by expressing OPG.
Molecular Mechanisms of Vascular Calcification
Because BMP-2 is a potent inducer of ectopic calcification, and an important factor in aortic calcification, 24 was detected at protein level mainly in HAECs and macrophages ( Figure 2A ). RANKL (10 ng/mL) increased the expression of BMP-2 mRNA in HAECs (2.5-fold) ( Figure  2B ). Because HAECs endogenously expressed OPG, we further studied the role of OPG in BMP-2 expression. As shown in Figure 2B , neutralizing anti-OPG antibody (anti-OPG) (0.1 g/ ml) significantly enhanced RANKL-induced BMP-2 expression. Increase in BMP-2 was confirmed at the protein level in the supernatant of HAECs treated with RANKL for 24 hours (4.6-and 5.2-fold with anti-OPG) ( Figure 2B ) and by Western blot analysis of total cell protein ( Figure 2C ). Of note, RANKL did not induce BMP-2 expression in monocytes and HASMCs even under the presence of neutralizing anti-OPG antibody (data not shown). BMP-2 (50 ng/mL) indeed induced the expression of osteogenic genes such as osteocalcin (OC), alkaline phosphatase (ALP), and OPN in HASMCs after 3 days stimulation ( Figure 2D ). The conditioned medium of HAECs stimulated with RANKL in the presence of anti-OPG during 2 days induced the expression of transcription factors related to osteogenesis (cbfa1, msh homeobox 2 [MSX2]) and bone-related genes (OC, and ALP) in HASMCs after 24 hours of incubation ( Figure 2E ). The addition of the BMP antagonist noggin (100 g/mL) abolished the osteogenic effect of the conditioned medium in HASMCs ( Figure 2E ). Therefore, under stimulation with RANKL, BMP is the main inducer of osteogenic differentiation secreted by HAECs. In contrast to BMP-2, MGP is reported to be a negative regulator of calcification. MGP strongly inhibits the precipitation of calcium salts 25 and blocks the osteoinductive properties of BMP by direct binding. 26 Stimulation with RANKL or neutralizing anti-OPG antibody significantly decreased MGP mRNA expression in HASMCs ( Figure 3A ) after 6 hours. Furthermore, similar to BMP-2, RANKL induced the mRNA expression of transcription factors cbfa1, MSX2 (msh homeobox 2), osterix, and the bone-related genes OC, and ALP in HASMCs after 3 days stimulation in the presence of neutralizing anti-OPG antibody, whereas RANKL alone did not induce ( Figure 3B and Online Figure II ). In addition, the continuous stimulation with RANKL increased the number of calcified nodules, as assessed by Alizarin red staining in HASMCs under osteogenic-inducible culture condition during 21 days (Figure 3C ), accompanied with increased ALP, and decreased MGP mRNA level expression, and no significant change in BMP-2 expression ( Figure 3D ). These results suggest that RANK stimulation in the atherosclerotic area may contribute to calcification by inducing BMP-2 expression in HAECs, decrease of MGP, induction of bone-related gene expression, and increase in the mineral deposition in HASMCs.
Effect of Estrogen on Calcification in RANKL-Stimulated HAECs and HASMCs
We further examined the effect of estrogen on RANKL-induced vascular calcification and found that estrogen, in a concentration equivalent to pharmacological levels found in target tissue (3.67 pmol/mL), 27 significantly attenuated RANKL-induced BMP-2 mRNA expression in HAECs ( Figure 4A ), whereas estrogen significantly increased MGP expression in HASMCs ( Figure  4B ). The estrogen receptor inhibitor ICI-182,780 abrogated those estrogen effects ( Figure 4B and 4C) . We verified the relevance of the MGP increase induced by estrogen in inhibiting RANKL-BMP osteogenic pathway. Pretreatment with estrogen during 24 hours inhibited the protein expression of osteogenic transcription factor cbfa1 induced by BMP-2 in HASMCs after 24 hours of stimulation. Knockdown of MGP by siRNA cancelled the protective effect of estrogen pretreatment, as shown by an increase in cbfa1 expression ( Figure 4D ).
Taken together, the results suggest that estrogen can dually block the RANKL-induced osteogenic pathways through an estrogen receptor-dependent manner.
Estrogen Receptor Isoforms in Vascular and Bone Cells
We next evaluated which estrogen receptor (ER) isoform regulated the estrogen response against vascular calcification and osteoporosis. The ER␣ mRNA level was higher than ER␤ in HASMCs, and they were expressed at the same level in HAECs and OBs ( Figure 5A ). The addition of selective ER agonists inhibited the RANKL-induced BMP-2 protein increase in HAECs, with a stronger effect of the ER␣ agonist PPT, compared to ER␤ agonist DPN ( Figure 5B ). In HASMCs, only PPT significantly increased MGP ( Figure 5C ). In osteoblasts, PPT decreased RANKL and increased OPG protein expression after 24 hours of stimulation, without significant changes in DPN-treated group ( Figure 5D ). These results show that estrogen simultaneously inhibits osteogenic pathway in vascular cells and decreases RANKL/OPG ratio in osteoblasts by acting mainly through ER␣.
The Mouse Model for Vascular Calcification and Osteoporosis
To examine the molecular mechanism underlying osteoporosis and vascular calcification in vivo, we developed the mouse model for vascular calcification and osteoporosis using ApoEdeficient mice. Although it was reported that old ApoE-deficient mice developed calcified lesions in the innominate arteries by 75 weeks of age, 28 we modified the ApoE-deficient mice model with estrogen deficiency by ovariectomy (OVX) and treatment with Western high-fat diet (HF) for 3 months.
Aortic calcification could be detected by Alizarin red staining only in mice with estrogen deficiency (OVX) and HF diet but was not observed in HF diet alone, regardless of the presence of atherosclerosis ( Figure 6A) . Quantification of the atherosclerotic lesion showed that calcified areas were significantly increased in the OVX/HF group, despite no significant difference in the atherosclerotic area compared to only HF group ( Figure 6B) .
Similarly, tartrate resistance acid phosphatase staining, which reflects osteoclast number, was significantly increased in the tibia of ovariectomized mice (Online Figure IV, A) . Furthermore, the bone mineral density was significantly decreased by OVX: decrease in the number of trabeculas and increase in the space between them, as quantified by microcomputed tomography (Online Figure IV, B) . The animal model exhibited typical features of the postmenopausal women with both aortic calcification and osteoporosis. Of note, we could not detect osteoclast-like cells in the calcified plaque of our animal model (data not shown).
In situ hybridization in aortas of HF/OVX group showed strong expression of the osteogenic marker OPN inside the atherosclerotic lesion, which suggests the intima calcification ( Figure 6C ). In sagittal sections, expression of RANK and RANKL mRNA were mainly found at medial layers and at outer membrane of atherosclerotic lesions, with detectable expression in endothelium, as indicated by arrows in Figure 6C .
Quantitative real-time PCR analysis demonstrated that OVX increased RANK, RANKL, and OPG expression ( Figure 7A ) in aorta. Estrogen deficiency also increased the BMP-2 expression in aorta, whereas in combination with HF diet, it increased the expression of calcification marker ALP. MGP level significantly decreased after OVX and/or HF diet ( Figure 7B ).
Prevention of Vascular Calcification and Osteoporosis by Estrogen Replacement
We replaced E2 simultaneously to the bilateral OVX and treated the mice with HF diet during 3 months. The estrogen was continuously administrated by osmotic mini pump in a concentration of 20 g/kg per day. This dose was enough to prevent tartrate resistance acid phosphatase activity and osteoporosis induced by OVX (Online Figure IV, A and B) . Importantly, estrogen replacement significantly decreased the atherosclerotic plaque and calcification induced by HF diet and estrogen deficiency, as shown by Oil red and Alizarin red staining ( Figure 6A ). Consistently, estrogen replacement attenuated OVX-induced increase in RANK, RANKL, OPG, BMP-2, and ALP mRNA levels, while simultaneously increasing MGP expression in vasculature, as quantified by real-time PCR (Figure 7A and 7B ). In addition, estrogen decreased the phosphorylation of smad-1/5/8 in aorta of HF/OVX mice as early as 2 weeks from the start of the animal experiment ( Figure 7C ), which suggests that estrogen may also reduce the BMP proosteogenic signaling in vivo.
Discussion
Epidemiological studies relate incidence of aortic calcification with low bone mineral density in postmenopausal women. 2 Similarly, OPG-deficient mice develop severe osteoporosis and vascular medial calcification. 9 In the absence of OPG, RANKL induces exaggerated osteoclast formation, followed by osteoporosis. In this study, we report that in the vasculature, RANKL induces osteogenesis by acting on 2 important molecules of the calcification process: BMP-2, an inducer of calcification, and MGP, a calcification inhibitor. In addition, estrogen acts mainly through ER␣ to counteract these effects of RANKL stimulation.
MGP inhibits calcium deposition, 25 and it binds to BMP-2, preventing the promotion of calcification. MGP has been detected at the site of calcification in vivo, 3 and an increase in MGP expression following calcification in vitro has also been reported 26 ; however, it may reflect a compensatory mechanism to inhibit calcification because analysis of MGP-deficient mice showed calcification in aorta and its branches, 29 and rats treated with warfarin, a vitamin K antagonist that interferes in the MGP processing, presented increased levels of vascular calcification. 30 Moreover, it was reported that the amount of MGP alone does not determine the calcification incidence, but the ratio of MGP to BMP-2 is what regulates mineral deposition and osteogenic differentiation: low levels (Ͻ1-fold) or high levels (Ͼ15-fold) favor calcification, whereas intermediates levels inhibit the process. 26 Our results showed that RANKL increased BMP-2 ( Figure 2C and 2D ) and decreased MGP expression ( Figure 3A ). Therefore we postulate that RANKL stimulation induces the low ratio of MGP to BMP-2 in vessel wall, which strongly induces calcification.
Importantly, it has been reported that systemic mineral imbalance caused by nephrectomy and calcitriol treatment induced RANKL expression in vasculature and consequent BMP-4 expression in vascular smooth muscle cells, which resulted in medial calcification. 31 Therefore, we speculate that some effects attributed in our study to BMP-2 may also be attributable to BMP-4 and that the RANKL system may contribute to vascular calcification by regulating BMP expression in both hypercholesterolemic and nonhypercholesterolemic condition.
RANKL alone was not able to induce calcification in HASMCs, but it induced bone-related gene expression (Figure 3B) and increased the number of calcified nodules of HASMCs cultured with osteogenic-inducible medium (Figure 3C) , which was accompanied by decreased MGP and increased ALP expression ( Figure 3D) .
Notably, estrogen acted mainly through ER␣ and inhibited the RANKL-induced BMP-2 expression ( Figure 5B ) and induced MGP expression ( Figure 5C ) in vascular cells. Early coronary calcification has been associated with loss of ER␣ in one man lacking functional ER␣, 32 and, in contrast, ER␤ expression correlated with calcium content, plaque area, and calcium-to-plaque ratio. 33 The associations of ER␤ with atherosclerotic calcification and ER␣ with vascular protective effects of estrogen highlight the complexity of estrogen action in vasculature, especially because many factors may modulate the ER␣ to ER␤ ratio. For example, increase in calcification in testosterone-treated ApoE-deficient mice was associated with an androgen receptor-mediated pathway for osteogenesis and to a decrease in ER␣ expression in the calcified vessel. 34 Our findings suggested that ER␣ mediates the estrogen-protective effect against calcification, and further works are required to clarify the opposite action of ER␤ in vascular calcification.
The detection of RANK and RANKL mRNA by in situ hybridization in the vessel wall and in the plaque ( Figure 6C ) suggested vascular responsiveness to RANKL in the calcification context. RANKL and BMP-2 expression increased in the total mRNA of aorta from estrogen deficient and/or high fat treated mice ( Figure 7A ), and estrogen replacement decreased the expression of RANKL system back to basal levels, and significantly increased the expression of MGP ( Figure 7B ). Importantly, serum OPG and RANKL have been reported to not account for the association between osteoporosis and vascular calcification in postmenopausal women under hormone therapy. 35 Based on our findings, we postulate that vascular calcification and osteoporosis resulted from RANK stimulation by locally expressed RANKL and not by circulating RANKL.
Vascular calcification has been induced in vitro by mineralocorticoid receptor activation in a mechanism independent of BMP-2 signaling, 36 and estrogen deficiency was also related to vascular calcification in an ovariectomized and HF diet-treated rabbit model. However, in contrast to our mouse model, it was reported a decrease in RANKL protein level in calcified aorta, and the calcification was not related to BMP-2 increase in vasculature. 17 Time course differences in the RANKL expression may explain the discrepancy, because in that rabbit model, the decrease in RANKL expression was observed after 15 months, whereas in our model, the increase in RANKL was detected after 3 months. Moreover, the atherosclerotic lesion was induced by double endothelial denudation, in contrast to the presence of intact endothelium in the atherosclerotic plaque of our animal model ( Figure 6C ). It may also explain the discrepancy in BMP-2 expression between the 2 studies, because our findings showed that endothelial cells are the main source of BMP-2 in vasculature. Importantly, our findings suggest that RANKL mediates calcification by inducing BMP-2 in HAECs and regulating MGP and osteogenesis in HASMCs; therefore, the autocrine and paracrine mechanisms activated by RANKL in both cells actively contribute to calcification in vasculature. Calcification results from complex mechanisms and the RANKL-BMP-2 axis may not be the unique pathway regulating this process in different conditions.
One limitation of our study is that the benefit of estrogen in preventing vascular calcification could not be confirmed in vivo because estrogen prevented atherosclerotic plaque development in the first place ( Figure 6A ). However, 2 weeks after OVX and HF diet, we were able to find an increase in phosphorylation of phospho-smad-1/5/8 in aorta but not in the estrogen-replacement group, which suggest that despite its limitation estrogen may reduce the BMP pro-osteogenic signaling in our model. In bone, the estrogen deficiency led to increased osteoclast number and osteoporosis (Online Figure  IV, A and B) . RANK-RANKL system has been widely studied in bone, in which osteoblasts express RANKL, which regulates osteoclast differentiation and activation. 5 Estrogen promotes bone formation by increasing OPG expression in osteoblast 12 and also by inducing osteoclast apoptosis via ER␣. 11 We confirmed that estrogen replacement decreased the osteoclast burden (Online Figure IV, A) and increased bone formation (Online Figure IV, B) and that ER␣ mediated the estrogen-induced OPG expression and RANKL decrease in osteoblast, as shown in Figure 5D . Taken together, we postulate that estrogen may be the key modulator of RANK-RANKL signaling in the development of both aortic calcification and osteoporosis.
Large prevention trial in the United States failed to confirm the protective effect of estrogen alone, or estrogen combined with progestin hormone therapy on coronary heart diseases. 37, 38 However, subgroup analyses of the Women's Health Initiative study have shown that women in whom hormone therapy was initiated at a younger age (50 to 59 years) and earlier after menopause tended to have reduced risk of coronary heart disease and total mortality, 39, 40 and an ancillary study showed a significant reduction in coronary artery calcium (Agatston) score in younger (50 to 59 years) women randomized to conjugated estrogen compared to placebo, indicating a reduced calcified plaque burden. 16 The data reported herein are consistent with these protective effects of estrogen observed as vascular calcification decrease in postmenopausal women and further suggest that the beneficial effect of estrogen in vascular calcification may be explained by inhibition of RANK-RANKL signaling and expression, thus implying a crosstalk of estrogen and RANKL in the arterial wall. The underlying mechanism remains to be elucidated, and ovariectomized ApoE-deficient mice provide a useful model to examine interventions for both osteoporosis and vascular calcification.
